Regeneron COVID-19 therapy cuts deaths among hospitalised patients who lack antibodies -study

A COVID-19 antibody cocktail developed by Regeneron Pharmaceuticals Inc and Roche reduced deaths in hospitalised patients whose own immune systems had failed to produce a response, a large British study found on Wednesday. The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate COVID-19 in the United States, but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised patients. It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with COVID-19 whose immune system had not mounted an antibody response, known as seronegative.